Information  X 
Enter a valid email address

Shield Therapeutics (STX)

  Print   

Wednesday 31 March, 2021

Shield Therapeutics

Block Listing 6 Monthly Return

RNS Number : 1728U
Shield Therapeutics PLC
31 March 2021
 

Shield Therapeutics plc

("Shield" or the "Group")

 

Block Listing 6 Monthly Return

 

Date: 31 March 2021

 

 Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

S hield Therapeutics Retention Share Plan

Period of return:

From:

01 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

54,219

Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-14,425

Equals:   Balance under scheme(s) not yet issued/allotted at end of period:

39,794

         

 

Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

Shield Therapeutics plc 2016 Company Share Option Plan

Period of return:

From:

01 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

388,079

Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:   Balance under scheme(s) not yet issued/allotted at end of period:

388,079

         

 

 

 Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

The Shield Therapeutics plc 2016 Long Term Incentive Plan

Period of return:

From:

01 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

171,883

Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-147,610

Equals:   Balance under scheme(s) not yet issued/allotted at end of period:

24,273

         

 

 

Name of applicant:

SHIELD THERAPEUTICS PLC

Name of scheme:

Shield Therapeutics Retention and Performance Share Plan

Period of return:

From:

01 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

1,885,819

Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2,500,000*

Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-1,207,543

Equals:   Balance under scheme(s) not yet issued/allotted at end of period:

3,178,276

         

*Please note this number is further to the block listing applied for on the 24th March 2021 and admitted on 30th March 2021. This block listing has been allocated to the Shield Therapeutics Retention and Performance Share Plan in entirety.

 

Name of contact:

Lucy Huntington-Bailey

Telephone number of contact:

+44 (0) 191 511 8500

 

 

For further information, please contact:

 

Shield Therapeutics plc

+44 (0) 191 511 8500

Tim Watts (CEO)

Lucy Huntington-Bailey, (Company Secretary and General Counsel)

 

 

 

Peel Hunt LLP - Nominated Adviser & Joint Broker

  +44 (0) 20 7148 8900

James Steel / Christopher Golden

 

 

 

finnCap Ltd - Joint Broker

  +44 (0) 20 7220 0500

Geoff Nash / Alice Lane / Matthew Radley

 

 

 

Walbrook PR - Financial PR & IR Adviser

+44 (0) 20 7933 8780

Paul McManus / Lianne Cawthorne

or [email protected]

       

 

 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

 

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREADDFDSEFEFA

a d v e r t i s e m e n t